Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
Daily Maverick on MSN14h
Navigating the cancer crisis: a mother’s fight for affordable treatment amidst rising costsTwenty-four-year-old Caitlyn Micholson is fighting cancer and for a chance to access lifesaving alternative treatment that is ...
India's Union Budget 2025-26 proposes cutting 7 customs tariff rates for industrial goods, reducing total slabs to 8, ...
Panjim: The Goa Health Department, alongside AstraZeneca and Qure.ai, is launching multiple initiatives to improve cancer ...
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
SHANGHAI, China I 5, 2025 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as ...
Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...
As the cancer day care centre at AIIMS, Delhi, spills over, families hope decentralised treatment will cut costs, minimise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback